Anti-Leukotriene B4 Receptor 2 antibody (ab84600)
Key features and details
- Rabbit polyclonal to Leukotriene B4 Receptor 2
- Suitable for: WB
- Reacts with: Human
- Isotype: IgG
Overview
-
Product name
Anti-Leukotriene B4 Receptor 2 antibody -
Description
Rabbit polyclonal to Leukotriene B4 Receptor 2 -
Host species
Rabbit -
Tested applications
Suitable for: WBmore details
Unsuitable for: ICC/IF -
Species reactivity
Reacts with: Human
Predicted to work with: Mouse, Rat -
Immunogen
Synthetic peptide corresponding to Human Leukotriene B4 Receptor 2 aa 150-250 conjugated to keyhole limpet haemocyanin.
(Peptide available asab94553) -
Positive control
- This antibody gave a positive signal in Human brain tissue lysate.
-
General notes
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle. -
Storage buffer
pH: 7.40
Preservative: 0.02% Sodium azide
Constituent: PBS
Batches of this product that have a concentration < 1mg/ml may have BSA added as a stabilising agent. If you would like information about the formulation of a specific lot, please contact our scientific support team who will be happy to help. -
Concentration information loading...
-
Purity
Immunogen affinity purified -
Clonality
Polyclonal -
Isotype
IgG -
Research areas
Associated products
-
Compatible Secondaries
-
Isotype control
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab84600 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
WB |
Use a concentration of 1 µg/ml. Detects a band of approximately 41 kDa (predicted molecular weight: 41 kDa).
|
Notes |
---|
WB
Use a concentration of 1 µg/ml. Detects a band of approximately 41 kDa (predicted molecular weight: 41 kDa). |
Target
-
Function
Low-affinity receptor for leukotrienes including leukotriene B4. Mediates chemotaxis of granulocytes and macrophages. The response is mediated via G-proteins that activate a phosphatidylinositol-calcium second messenger system. The rank order of affinities for the leukotrienes is LTB4 > 12-epi-LTB4 > LTB5 > LTB3. -
Tissue specificity
Widely expressed. -
Sequence similarities
Belongs to the G-protein coupled receptor 1 family. -
Cellular localization
Cell membrane. - Information by UniProt
-
Database links
- Entrez Gene: 56413 Human
- Entrez Gene: 57260 Mouse
- Entrez Gene: 114098 Rat
- Omim: 605773 Human
- SwissProt: Q9NPC1 Human
- SwissProt: Q9JJL9 Mouse
- SwissProt: Q924U0 Rat
- Unigene: 642693 Human
see all -
Alternative names
- BLT2R antibody
- JULF2 antibody
- Leukotriene B4 receptor 2 antibody
see all
Images
-
Anti-Leukotriene B4 Receptor 2 antibody (ab84600) at 1 µg/ml + Human brain tissue lysate - total protein (ab29466) at 10 µg
Secondary
Goat polyclonal to Rabbit IgG - H&L - Pre-Adsorbed (HRP) at 1/3000 dilution
Developed using the ECL technique.
Performed under reducing conditions.
Predicted band size: 41 kDa
Observed band size: 41 kDa
Exposure time: 15 minutes
Protocols
Datasheets and documents
-
SDS download
-
Datasheet download
References (2)
ab84600 has been referenced in 2 publications.
- Liu G et al. A novel inflammation-associated prognostic signature for clear cell renal cell carcinoma. Oncol Lett 24:307 (2022). PubMed: 35949606
- Su KK et al. Five-lipoxygenase-activating protein-mediated CYLD attenuation is a candidate driver in hepatic malignant lesion. Front Oncol 12:912881 (2022). PubMed: 35978827